About International Pharmacopoeia
The International Pharmacopoeia (Ph. Int.) is published by WHO with the aim to provide specifications and test methods for priority medicines of major public health importance, for example, listed in the WHO Model List of Essential Medicines, recommended by specific WHO disease programmes, as well as medicines for children. Priority is also given to medicines evaluated by the Medicines Prequalification Programme. Access to priority medicines shall also be increased by global harmonization of quality specifications for selected pharmaceutical products, excipients and dosage forms. The activities related to Ph. Int. are an essential element in the overall quality control and assurance of pharmaceuticals contributing to the safety and efficacy of medicines.
The work on The International Pharmacopoeia is carried out in collaboration with members of the WHO Expert Advisory Panel on The International Pharmacopoeia, the WHO Expert Committee on Specifications for Pharmaceutical Preparations and other specialists. The process involves the consultation of and input from WHO Member States’ drug regulatory authorities and national drug quality control laboratories, WHO collaborating Centres, standard-setting organizations and manufacturers around the world.
Resource link:
International Pharmacopoeia (Ph. Int.)
First Year B Pharm Notes, Syllabus, Books, PDF Subjectwise/Topicwise
Recommended readings
Performance Monitoring and Updates in AI-Enabled Medical Devices: FDA’s Guiding Principles
Lifecycle Management in AI-Enabled Medical Devices: FDA’s Comprehensive Framework
Data Management in AI-Enabled Medical Devices: Key to Safety and Effectiveness
